blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1618879

EP1618879 - Injectable formulation of paclitaxel for cad treatment [Right-click to bookmark this link]
Former [2006/04]Injectable formulations of taxanes for cad treatment
[2012/38]
StatusNo opposition filed within time limit
Status updated on  03.01.2014
Database last updated on 05.07.2024
Most recent event   Tooltip17.07.2015Lapse of the patent in a contracting state
New state(s): HU, LU		published on 19.08.2015  [2015/34]
Applicant(s)For all designated states
Cordis Corporation
14201 N.W. 60th Avenue
Miami Lakes
Florida 33014 / US
[N/P]
Former [2006/04]For all designated states
Cordis Corporation
14201 N.W. 60th Avenue Miami Lakes
Florida 33014 / US
Inventor(s)01 / Falotico, Robert
40 Black Horse Run
Belle Mead, NJ 08502 / US
02 / Zhao, Jonathon Z.
12 Briar Hill Cout
Belle Mead, NJ 08502 / US
 [2006/04]
Representative(s)Belcher, Simon James
Urquhart-Dykes & Lord LLP
Arena Point
Merrion Way
Leeds LS2 8PA / GB
[N/P]
Former [2013/09]Belcher, Simon James
Urquhart-Dykes & Lord LLP Tower North Central Merrion Way
Leeds LS2 8PA / GB
Former [2006/04]Belcher, Simon James
Urquhart-Dykes & Lord LLP Tower North Central Merrion Way
Leeds LS2 8PA / GB
Application number, filing date05253046.618.05.2005
[2006/04]
Priority number, dateUS2004085895402.06.2004         Original published format: US 858954
[2006/04]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP1618879
Date:25.01.2006
Language:EN
[2006/04]
Type: B1 Patent specification 
No.:EP1618879
Date:27.02.2013
Language:EN
[2013/09]
Search report(s)(Supplementary) European search report - dispatched on:EP14.11.2005
ClassificationIPC:A61K9/19, A61K47/22, A61K9/00, A61K31/337
[2012/38]
CPC:
A61K9/0019 (EP,US); A61K31/337 (EP,US); A61K47/22 (EP,US);
A61K9/19 (EP,US); A61P29/00 (EP); A61P35/04 (EP);
A61P37/00 (EP); A61P43/00 (EP); A61P7/00 (EP);
A61P7/02 (EP); A61P9/00 (EP); A61P9/10 (EP);
A61P9/14 (EP) (-)
Former IPC [2006/04]A61K31/337
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2006/04]
TitleGerman:Injizierbare Formulierung von Paclitaxel zur KHK-Behandlung[2012/38]
English:Injectable formulation of paclitaxel for cad treatment[2012/38]
French:Formulation injectable de paclitaxel pour le traitement de la coronaropathie[2012/38]
Former [2006/04]Injizierbare Formulierungen von Taxanen zur KHK-Behandlung
Former [2006/04]Injectable formulations of taxanes for cad treatment
Former [2006/04]Formulations injectables de taxanes pour le traitement de la coronaropathie
Examination procedure30.03.2006Examination requested  [2006/21]
05.09.2006Despatch of a communication from the examining division (Time limit: M06)
08.03.2007Reply to a communication from the examining division
03.05.2007Despatch of a communication from the examining division (Time limit: M04)
06.06.2007Reply to a communication from the examining division
04.02.2009Despatch of a communication from the examining division (Time limit: M04)
30.05.2009Reply to a communication from the examining division
14.01.2010Despatch of a communication from the examining division (Time limit: M06)
31.08.2010Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
29.10.2010Reply to a communication from the examining division
06.10.2011Despatch of a communication from the examining division (Time limit: M04)
07.02.2012Reply to a communication from the examining division
05.10.2012Communication of intention to grant the patent
10.01.2013Fee for grant paid
10.01.2013Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  05.09.2006
Opposition(s)28.11.2013No opposition filed within time limit [2014/06]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
29.10.2010Request for further processing filed
29.10.2010Full payment received (date of receipt of payment)
Request granted
11.11.2010Decision despatched
Fees paidRenewal fee
14.05.2007Renewal fee patent year 03
28.03.2008Renewal fee patent year 04
12.05.2009Renewal fee patent year 05
31.03.2010Renewal fee patent year 06
11.05.2011Renewal fee patent year 07
29.03.2012Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU18.05.2005
AT27.02.2013
CY27.02.2013
CZ27.02.2013
DK27.02.2013
EE27.02.2013
FI27.02.2013
LT27.02.2013
MC27.02.2013
PL27.02.2013
RO27.02.2013
SE27.02.2013
SI27.02.2013
SK27.02.2013
TR27.02.2013
LU18.05.2013
BG27.05.2013
GR28.05.2013
ES07.06.2013
IS27.06.2013
PT27.06.2013
[2015/34]
Former [2015/32]AT27.02.2013
CY27.02.2013
CZ27.02.2013
DK27.02.2013
EE27.02.2013
FI27.02.2013
LT27.02.2013
MC27.02.2013
PL27.02.2013
RO27.02.2013
SE27.02.2013
SI27.02.2013
SK27.02.2013
TR27.02.2013
BG27.05.2013
GR28.05.2013
ES07.06.2013
IS27.06.2013
PT27.06.2013
Former [2014/03]AT27.02.2013
CY27.02.2013
CZ27.02.2013
DK27.02.2013
EE27.02.2013
FI27.02.2013
LT27.02.2013
MC27.02.2013
PL27.02.2013
RO27.02.2013
SE27.02.2013
SI27.02.2013
SK27.02.2013
BG27.05.2013
GR28.05.2013
ES07.06.2013
IS27.06.2013
PT27.06.2013
Former [2013/52]AT27.02.2013
CY27.02.2013
CZ27.02.2013
DK27.02.2013
EE27.02.2013
FI27.02.2013
LT27.02.2013
PL27.02.2013
RO27.02.2013
SE27.02.2013
SI27.02.2013
SK27.02.2013
BG27.05.2013
GR28.05.2013
ES07.06.2013
IS27.06.2013
PT27.06.2013
Former [2013/49]AT27.02.2013
CZ27.02.2013
DK27.02.2013
EE27.02.2013
FI27.02.2013
LT27.02.2013
PL27.02.2013
RO27.02.2013
SE27.02.2013
SI27.02.2013
SK27.02.2013
BG27.05.2013
GR28.05.2013
ES07.06.2013
IS27.06.2013
PT27.06.2013
Former [2013/48]AT27.02.2013
DK27.02.2013
EE27.02.2013
FI27.02.2013
LT27.02.2013
PL27.02.2013
SE27.02.2013
SI27.02.2013
BG27.05.2013
GR28.05.2013
ES07.06.2013
IS27.06.2013
PT27.06.2013
Former [2013/40]AT27.02.2013
FI27.02.2013
LT27.02.2013
PL27.02.2013
SE27.02.2013
SI27.02.2013
BG27.05.2013
GR28.05.2013
ES07.06.2013
IS27.06.2013
PT27.06.2013
Former [2013/37]AT27.02.2013
FI27.02.2013
LT27.02.2013
PL27.02.2013
SE27.02.2013
SI27.02.2013
BG27.05.2013
GR28.05.2013
ES07.06.2013
IS27.06.2013
Former [2013/36]AT27.02.2013
LT27.02.2013
PL27.02.2013
SE27.02.2013
BG27.05.2013
ES07.06.2013
IS27.06.2013
Former [2013/34]LT27.02.2013
SE27.02.2013
BG27.05.2013
IS27.06.2013
Former [2013/33]LT27.02.2013
Documents cited:Search[X]WO9945918  (NAPRO BIOTHERAPEUTICS INC [US]) [X] 1-10 * page 2, lines 14-31 * * page 3, lines 6-13 * * examples 1-11 *;
 [X]WO0071163  (SONUS PHARMA INC [US], et al) [X] 1-10 * page 8, lines 1-15 * * page 11, line 27 - page 12, line 6 * * page 16, lines 11-31 * * page 23, line 23 - page 24, line 11 * * example 4 *;
 [X]WO0130319  (SUPERGEN INC [US], et al) [X] 1-10 * page 3, line 32 - page 5, line 5; claims 1,3,5 * * examples 1-3 *;
 [X]WO0243765  (TRANSFORM PHARMACEUTICALS INC [US], et al) [X] 1-10 * page 4, lines 8-36 * * page 8, lines 24-31 * * page 10, lines 3-6 * * page 14, lines 5-21 *;
 [X]WO03057208  (IVAX RESEARCH INC [US]) [X] 1-10 * paragraphs [0017] , [0021] , [0022] , [0029] , [0031] , [0032] , [0047] , [0048] * * figures 1,2 *;
 [PX]WO2004091506  (IVAX RESEARCH INC [US], et al) [PX] 1-10* claims 1-8 *
by applicantUS5924997
 US6245026
    - CLOWES, A.W.; KARNOVSKY M., NATURE, (1977), vol. 265, pages 25 - 26
    - GUYTON, J.R. ET AL., CIRC. RES., (1980), vol. 46, pages 625 - 634
    - CLOWES, A.W.; CLOWES, M.M., LAB. INVEST., (1985), vol. 52, pages 611 - 616
    - CLOWES, A.W.; CLOWES, M.M., CIRC. RES., (1986), vol. 58, pages 839 - 845
    - MAJESKY ET AL., CIRC. RES., (1987), vol. 61, pages 296 - 300
    - SNOW ET AL., AM. J. PATHOL., (1990), vol. 137, pages 313 - 330
    - OKADA, T. ET AL., NEUROSURGERY, (1989), vol. 25, pages 92 - 98
    - CURRIER, J.W. ET AL., CIRC., (1989), vol. 80, pages 11 - 66
    - SOLLOT, S.J. ET AL., J. CLIN. INVEST., (1995), vol. 95, pages 1869 - 1876
    - POWELL, J.S. ET AL., SCIENCE, (1989), vol. 245, pages 186 - 188
    - LUNDERGAN, C.F. ET AL., AM. J. CARDIOL., (1991), vol. 17, no. B, pages 132B - 136B
    - JONASSON, L. ET AL., PROC. NATL., ACAD. SCI., (1988), vol. 85, page 2303
    - FERNS, G.A.A. ET AL., SCIENCE, (1991), vol. 253, pages 1129 - 1132
    - NEMECEK, G.M. ET AL., J. PHARMACOL. EXP. THERA., (1989), vol. 248, pages 1167 - 1174
    - LIU, M.W. ET AL., CIRC., (1990), vol. 81, pages 1089 - 1093
    - FUKUYAMA, J. ET AL., EUR. J. PHARMACOL., (1996), vol. 318, pages 327 - 332
    - HANSSON, G.K.; HOLM, J., CIRC., (1991), vol. 84, pages 1266 - 1272
    - MARX, S.O. ET AL., CIRC. RES., (1995), vol. 76, pages 412 - 417
    - COLBURN, M.D. ET AL., J. VASC. SURG., (1992), vol. 15, pages 510 - 518
    - BERK, B.C. ET AL., J. AM. COLL. CARDIOL., (1991), vol. 17, pages 111B - 117B
    - WEINBERGER, J. ET AL., INT. J. RAD. ONC. BIOL. PHYS., (1996), vol. 36, pages 767 - 775
    - FARB, A. ET AL., CIRC. RES., (1997), vol. 80, pages 542 - 550
    - SIMONS, M. ET AL., NATURE, (1992), vol. 359, pages 67 - 70
    - CHANG, M.W. ET AL., J. CLIN. INVEST., (1995), vol. 96, pages 2260 - 2268
    - TETRAHEDRON LETTERS, (1994), vol. 35, no. 52, pages 9709 - 9712
    - J. MED. CHEM., (1992), vol. 35, pages 4230 - 4237
    - J. MED. CHEM., (1991), vol. 34, pages 992 - 998
    - J. NATURAL PROD., (1994), vol. 57, no. 10, pages 1404 - 1410
    - J. NATURAL PROD., (1994), vol. 57, no. 11, pages 1580 - 1583
    - J. AM. CHEM. SOC., (1988), vol. 110, pages 6558 - 6560
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.